Physician profile
Vinod Gulati
NPI 1306852942
$9,383.29
in general payments reported to CMS, 2019-2025
48 companies · $922 in 2025
The $922 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $585 · 2021: $1,167 · 2022: $1,047 · 2023: $3,943 · 2024: $1,013 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,078 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,960 · Consulting Fee: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,078.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,960.00 |
| Consulting Fee | $840.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $3,077.74 | 2023 | Adlarity |
| Astrazeneca Pharmaceuticals LP | $1,520.32 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $496.14 | 2020-2025 | Rexulti |
| Novo Nordisk INC | $495.16 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $426.33 | 2019-2024 | |
| Glaxosmithkline, LLC. | $412.40 | 2021-2025 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $281.21 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $189.14 | 2019-2024 | Xarelto |
| Evoke Pharma, INC. | $175.46 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $155.74 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $154.15 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $154.11 | 2020-2021 | |
| Amarin Pharma, INC. | $126.30 | 2020-2021 | |
| Lundbeck LLC | $126.29 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $126.04 | 2019-2024 | Dificid |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $125.34 | 2024-2025 | Ibsrela |
| Axsome Therapeutics, INC. | $104.20 | 2025 | Auvelity |
| Djo, LLC | $103.73 | 2024 | Cmf |
| Abbott Laboratories | $100.72 | 2021-2022 | |
| Lilly USA, LLC | $97.36 | 2022-2025 | Mounjaro, Kisunla |
| Abbvie INC. | $89.92 | 2021 | |
| Astellas Pharma US INC | $89.19 | 2019-2024 | Veozah |
| Amgen INC. | $88.92 | 2025 | Repatha, Otezla |
| Cumberland Pharmaceuticals, INC. | $79.47 | 2025 | Kristalose |
| Inspire Medical Systems, INC. | $52.37 | 2025 | Inspire |
| Pfizer INC. | $51.20 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.50 | 2022 | |
| Urovant Sciences INC | $32.82 | 2022 | |
| Medtronic, INC. | $31.64 | 2025 | Percept PC Brainsense |
| Agios Pharmaceuticals, INC. | $30.63 | 2025 | Pyrukynd |
| Neurelis, INC. | $29.81 | 2023 | Valtoco |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.55 | 2021 | |
| Ucb, INC. | $26.05 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.70 | 2019 | |
| Renalytix Ai, INC. | $23.53 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Biocompatibles, INC. | $22.91 | 2019 | |
| Xeris Pharmaceuticals, INC. | $20.91 | 2021 | |
| Seqirus USA INC | $20.65 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Paratek Pharmaceuticals, INC. | $20.17 | 2025 | Xhance, Nuzyra |
| Shield Therapeutics INC | $19.96 | 2024 | |
| Allergan, INC. | $18.90 | 2020 | |
| Daiichi Sankyo INC. | $17.72 | 2024 | Injectafer |
| Currax Pharmaceuticals LLC | $16.42 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.33 | 2025 | Austedo Xr |
| Kowa Pharmaceuticals America, INC. | $14.55 | 2020 | |
| Vistapharm, INC. | $14.04 | 2021 | |
| Forte Bio-Pharma LLC | $12.45 | 2021 | |
| Sanofi Pasteur INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinod Gulati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.